Milsaperidone

Last updated

Milsaperidone
Milsaperidone.svg
Clinical data
Trade names Bysanti
Other namesVHX896
Routes of
administration 		Oral
Drug class Atypical antipsychotic
Identifiers
  • (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C24H29FN2O4
Molar mass 428.504 g·mol−1
3D model (JSmol)
  • C[C@@H](C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC)O
  • InChI=1S/C24H29FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-17,28H,3,8-13H2,1-2H3/t16-/m0/s1
  • Key:SBKZGLWZGZQVHA-INIZCTEOSA-N

Milsaperidone (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name), also known by its developmental code name VHX-896 and its tentative brand name Bysanti, is an atypical antipsychotic which is pending approval for the treatment of schizophrenia and bipolar disorder and is in phase 3 clinical trials for treatment of major depressive disorder. [1] [2] [3] It is a prodrug of iloperidone (Fanapt) and acts as a dopamine D2 receptor and serotonin 5-HT2A receptor antagonist, among other actions. [1] [4] [5] The drug was developed by Vanda Pharmaceuticals. [1]

See also

References

  1. 1 2 3 "Vanda Pharmaceuticals". AdisInsight. 30 July 2025. Retrieved 11 October 2025.
  2. ↑ IsHak WW, Hirsch D, Renteria S, Totlani J, Murphy N, Chang T, et al. (October 2025). "Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications". BMC Psychiatry. 25 (1) 939. doi: 10.1186/s12888-025-07141-3 . PMC   12506068 . PMID   41057811.
  3. ↑ Richmond LM (1 June 2025). "Med Check: FDA Accepts Bysanti Application, Cobenfy Fails as Adjunct, and More". Psychiatric News. 60 (6) appi.pn.2025.06.6.2. doi:10.1176/appi.pn.2025.06.6.2. ISSN   0033-2704 . Retrieved 11 October 2025.
  4. ↑ Kang J (9 May 2025). "Milsaperidone Under Review for Bipolar I Disorder and Schizophrenia". MPR. Retrieved 11 October 2025.
  5. ↑ "Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026". BioSpace. 5 May 2025. Retrieved 11 October 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.